Physician profile
Anna Bowers
NPI 1457130213
$3,918.13
in general payments reported to CMS, 2019-2025
27 companies · $2,205 in 2025
The $2,205 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $44.19 · 2024: $1,669 · 2025: $2,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,918.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $906.93 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $667.67 | 2024-2025 | |
| Lilly USA, LLC | $421.79 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $254.43 | 2024-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $203.04 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $185.63 | 2024-2025 | Veozah |
| Pfizer INC. | $132.05 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.42 | 2024-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.91 | 2024-2025 | Xifaxan |
| Amneal Pharmaceuticals LLC | $87.12 | 2025 | Unithroid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.25 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $77.73 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $72.52 | 2024-2025 | Sunosi |
| Exact Sciences Corporation | $71.18 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $67.58 | 2025 | Freestyle Libre 3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $64.75 | 2023-2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $61.69 | 2024-2025 | |
| Esperion Therapeutics, INC. | $55.16 | 2024-2025 | Nexletol |
| Glaxosmithkline, LLC. | $49.05 | 2025 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $44.92 | 2024-2025 | Zoryve |
| Aimmune Therapeutics, INC. | $36.11 | 2024-2025 | Zenpep |
| Shield Therapeutics INC | $35.36 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $29.89 | 2023-2024 | Quviviq |
| Bluewind Medical | $24.65 | 2025 | Revi |
| Dexcom, INC. | $23.00 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $19.27 | 2025 | Gemtesa |
| Ascensia Diabetes Care US INC. | $19.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.